Whilst this is all true, I personally don't think it will move the SP much.
@oaftar as Dr T pointed out recently, the Aussie Biotech Investor market is not too sophisticated. IMO there is also a few traders looking for a quick win and don't care too much about the science.
If you research the shares on issue and how they are held, it is clear most SHs are investors (not traders) in Race. Race is illiquid compared to other stocks. Perhaps read the recent quarterly thread and see the tables one poster puts up comparing the holdings. The typical large holders keep accumulating, as do I.
Of course, we are hopeful the release of the MOA will push the SP, but IMO it will likely take some form of commercialization such as licensing or partnership to light the wick. This commercialisation has been speculated about recently.
Some information discovered in the past week suggests some new trials could be started with other drug combinations for different cancers. Any new trials would likely need partner dollars to get off the ground.
IMO within the next three years we will see outsized returns in the current SP.
Will Race exist by then? ...or will it own Bisantrene remains to be seen.
I think Licencing/partnership is the likely path in the shorter term.
If you are a trader, good luck.
If you are an investor, good luck with your research and hopefully welcome onboard.
Cheers
(20min delay)